Head-To-Head Review: Genocea Biosciences (NASDAQ:GNCA) vs. Cortexyme (NASDAQ:CRTX)

Profitability

This table compares Genocea Biosciences and Cortexyme’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	-182.88%	-62.76%
Cortexyme	N/A	-70.96%	-63.53%

Risk & Volatility

Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, Cortexyme has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Valuation and Earnings

This table compares Genocea Biosciences and Cortexyme”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	$1.91 million	0.00	-$33.20 million	($0.61)	N/A
Cortexyme	N/A	N/A	-$89.94 million	($2.97)	-0.54

Genocea Biosciences has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 63.2% of Cortexyme shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 27.9% of Cortexyme shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Genocea Biosciences beats Cortexyme on 6 of the 9 factors compared between the two stocks.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

About Cortexyme

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.